American Society of Hematology

SHERPA: Blue

People

  1. Seshan
    Seshan
  2. Zelenetz
    Zelenetz
  3. Dogan
    Dogan
  4. Palomba
    Palomba
  5. Batlevi
    Batlevi
  6. Owens
    Owens
  7. Younes
    Younes
  8. Horwitz
    Horwitz
  9. Kumar
    Kumar
  10. Matasar
    Matasar

Groups

  1. Biostatistics Service (17)
  2. Center for Hematologic Malignancies (17)
  3. Center for Pancreatic Cancer Research (17)
  4. Department of Medicine (17)
  5. Epidemiology and Biostatistics (17)
  6. Hematologic Malignancies, Division of (17)
  7. Lymphoma (17)
  8. Executive Committee, Center for Hematologic Malignancies (12)
  9. GSK Faculty (10)
  10. Survivorship Research (10)
Search Within
  1. "Center for Pancreatic Cancer Research"
  2. "Lymphoma"
  3. "Ahmet Dogan"
Formats
  1. Meeting Abstract (14)
  2. Journal Article (3)
Groups
  1. Biostatistics Service (17)
  2. Center for Hematologic Malignancies (17)
  3. Center for Pancreatic Cancer Research (17)
  4. Department of Medicine (17)
  5. Epidemiology and Biostatistics (17)
  6. Hematologic Malignancies, Division of (17)

More Groups

People
  1. Ahmet Dogan (17)
  2. Venkatraman Seshan (16)
  3. Andrew Zelenetz (15)
  4. Maria Palomba (11)
  5. Anas Younes (9)
  6. Colette Owens (9)

More People

Years
  1. 2023 (3)
  2. 2022 (1)
  3. 2021 (4)
  4. 2020 (2)
  5. 2019 (2)
  6. 2015 (2)

More Years

Publications
  1. Blood (15)
  2. Blood Advances (2)

Results (17)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Genetic alterations of follicular lymphoma can predict response to very low dose radiotherapy
    Meeting Abstract

    Wijetunga, N. A.; Lebow, E.; Chan, A.; Fregonese, B.; Seshan, V.; Hajj, C.; Cederquist, G.; Hubbeling, H.; Ma, J.; Sarkar, R. R.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Real-world outcomes in patients with transformed follicular lymphoma treated with CD19-targeting CAR-T therapy
    Meeting Abstract

    Rivas-Delgado, A.; Luttwak, E.; Drill, E.; Goldstein, I.; Landego, I.; Tomas, A. A.; Parascondola, A.; Saldia, A.; Caron, P.; Dahi, P. B.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • A multicenter phase 2 trial of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in patients with treatment-naïve, TP53-mutant mantle cell lymphoma
    Meeting Abstract

    Kumar, A.; Soumerai, J.; Abramson, J. S.; Barnes, J. A.; Caron, P.; Chabowska, M.; Devlin, M.; Dogan, A.; Falchi, L.; Garcia, R. N.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Molecular profiling across lymphoma subtypes using MSK-impact next generation sequencing
    Meeting Abstract

    Batlevi, C. L.; Drill, E.; Okwali, M.; Ptashkin, R.; Caron, P. C.; Epstein-Peterson, Z. D.; Falchi, L.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Zanubrutinib, obinutuzumab, and venetoclax in chronic lymphocytic leukemia: Early MRD kinetics define a high-risk patient cohort with delayed bone marrow undetectable MRD and earlier post-treatment MRD recurrence
    Meeting Abstract

    Soumerai, J. D.; Mato, A. R.; Dogan, A.; Seshan, V.; Joffe, E.; Flaherty, K.; Carter, J.; Hochberg, E. P.; Barnes, J. A.; Hamilton, A.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Interim efficacy analysis of a phase II study demonstrates promising activity of the combination of pembrolizumab (PEM) and entinostat (ENT) in relapsed and refractory (R/R) Hodgkin lymphoma (HL)
    Meeting Abstract

    Sermer, D. J.; Vardhana, S.; Biggar, E.; Moskowitz, A. J.; Joffe, E.; Khan, N.; Straus, D. J.; Kumar, A.; Zelenetz, A. D.; Horwitz, S. M.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Preliminary safety and efficacy from a multicenter, investigator-initiated phase II study in untreated TP53 mutant mantle cell lymphoma with zanubrutinib, obinutuzumab, and venetoclax (BOVen)
    Meeting Abstract

    Kumar, A.; Soumerai, J. D.; Abramson, J. S.; Batlevi, C. L.; Chadha, P.; Dogan, A.; Falchi, L.; Flaherty, K.; Friedman, C.; Grieve, C.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Clinical characteristics and outcomes of extranodal stage I diffuse large B-cell lymphoma in the rituximab era
    Journal Article

    Bobillo, S.; Joffe, E.; Lavery, J. A.; Sermer, D.; Ghione, P.; Noy, A.; Caron, P. C.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • T follicular helper phenotype prendicts response to histone deacetylase inhibitors in relapsed/refractory peripheral T-cell lymphoma
    Journal Article

    Ghione, P.; Faruque, P.; Mehta-Shah, N.; Seshan, V.; Ozkaya, N.; Bhaskar, S.; Yeung, J.; Spinner, M. A.; Lunning, M.; Inghirami, G.; more...
    Blood Advances (2020)

    Fulltext@MSK | Save
  • Extra copies of MYC, BCL2, and BCL6 and outcome in patients with diffuse large B-cell lymphoma
    Journal Article

    Sermer, D.; Bobillo, S.; Dogan, A.; Zhang, Y.; Seshan, V.; Lavery, J. A.; Batlevi, C.; Caron, P.; Hamilton, A.; Hamlin, P.; more...
    Blood Advances (2020)

    Fulltext@MSK | Save